Amylyx prices 14.09 million share offering at $35.50, net proceeds about $471.7 million
On August 19, 2026, Amylyx entered an underwriting agreement to sell 14,090,000 new shares of common stock at $35.50 per share, with a 30-day option for underwriters to buy up to 2,113,500 more. Expected net proceeds are about $471.7 million, or about $542.5 million if the option is exercised in full, and the company plans to use them to fund a potential U.S. launch of avexitide if approved, add manufacturing capacity, and for research, working capital and general corporate purposes. The offering is expected to close on August 21, 2026, and the new shares add to the company's outstanding share count.
Key points
- 14,090,000 firm shares offered at $35.50 per share, all sold by the company
- Underwriters have a 30-day option to buy up to 2,113,500 additional shares
- Expected net proceeds of about $471.7 million, or about $542.5 million if the option is fully exercised
- Offering expected to close on August 21, 2026, subject to customary closing conditions
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 20, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.